Phibro Animal Health (NASDAQ: PAHC) reported Q4 EPS of $0.39, $0.06 better than the analyst estimate of $0.33. Revenue for the quarter came in at $195 million versus the consensus estimate of $192.47 million.

Highlights for the June 2017 quarter (compared to the June 2016 quarter)

• Net sales of $195 million, an increase of $6 million, or 3%
• Net income of $15 million, an increase of 1%
• Diluted EPS of $0.38, equal to the prior year
• Adjusted EBITDA of $29 million, an increase of $1 million, or 4%
• Adjusted diluted EPS of $0.39, an increase of $0.07, or 22%

Highlights for the June 2017 year (compared to the June 2016 year)

• Net sales of $764 million, an increase of $13 million, or 2%
• Net income of $65 million, a decrease of $18 million, or 22%
• Diluted EPS of $1.61, a decrease of $0.46, or 22%
• Adjusted EBITDA of $120 million, an increase of $6 million, or 5%
• Adjusted diluted EPS of $1.51, an increase of $0.08, or 6%

Guidance for the June 2018 year, compared to the June 2017 year

• Net sales of $765 - $790 million, an increase of $1 to $26 million, or 0% - 3%
• Net income of $58 - $63 million, a decrease of $7 to $2 million, or (10)% - (2)%
• Diluted EPS of $1.43 - $1.57, a decrease of $0.18 to $0.04, or (11)% - (3)%
• Adjusted EBITDA of $123 - $126 million, an increase of $3 to $6 million, or 3% - 5%
• Adjusted diluted EPS of $1.55 - $1.61, an increase of $0.04 to $0.10, or 3% - 7%

GUIDANCE:

Phibro Animal Health sees FY2018 EPS of $1.55-$1.61, versus the consensus of $1.54. Phibro Animal Health sees FY2018 revenue of $765-790 million, versus the consensus of $779.05 million.

For earnings history and earnings-related data on Phibro Animal Health (PAHC) click here.